Haemodialysis catheter infection reduction

0

Taylor, C., Cahill, J., Gerrish, M. and Little, J. (2008) A new haemodialysis catheter-locking agent reduces infections in haemodialysis patients. Journal of Renal Care. 34(3), p.116-20).

Abstract:

Background: Intravenous catheters for haemodialysis increase the risk of sepsis. This study investigates the use of a taurolidine/citrate catheter-locking agent for patients receiving hospital-based haemodialysis, auditing the number and cost of infections before and after its introduction.

Methods: The incidence and cost of treatment of catheter sepsis occurring in all patients receiving haemodialysis via a line were investigated over 6-month periods before and after introducing the taurolidine/citrate line-locking agent.

Results: A reduction of 4.62 infections per 1000 catheter days, or 88.5%, was shown after the introduction of the new line-locking agent.

The total costs of line infections in the first 6 months were €52 500, (£41 000); after the introduction of the taurolidine/citrate locks, these reduced to €33 300, (£26 000), a reduction of €19 200 (£15 000).

Conclusions: The use of a taurolidine/citrate haemodialysis catheter-locking agent in our haemodialysis population has significantly reduced the line sepsis rate, with a positive impact on morbidity, mortality and cost.

More IV news at IVTEAM
Taylor, C., Cahill, J., Gerrish, M. and Little, J. (2008) A new haemodialysis catheter-locking agent reduces infections in haemodialysis patients. Journal of Renal Care. 34(3), p.116-20).

Abstract:

Background: Intravenous catheters for haemodialysis increase the risk of sepsis. This study investigates the use of a taurolidine/citrate catheter-locking agent for patients receiving hospital-based haemodialysis, auditing the number and cost of infections before and after its introduction.

Methods: The incidence and cost of treatment of catheter sepsis occurring in all patients receiving haemodialysis via a line were investigated over 6-month periods before and after introducing the taurolidine/citrate line-locking agent.

Results: A reduction of 4.62 infections per 1000 catheter days, or 88.5%, was shown after the introduction of the new line-locking agent.

The total costs of line infections in the first 6 months were €52 500, (£41 000); after the introduction of the taurolidine/citrate locks, these reduced to €33 300, (£26 000), a reduction of €19 200 (£15 000).

Conclusions: The use of a taurolidine/citrate haemodialysis catheter-locking agent in our haemodialysis population has significantly reduced the line sepsis rate, with a positive impact on morbidity, mortality and cost.

More IV news at IVTEAM

Share.

Comments are closed.

Free Email Updates
Join 5.5K IVTEAM members. Subscribe now and be the first to receive all the latest free updates from IVTEAM!
100% Privacy. We don't spam.